Exactly what I thought. We will be in a 3-3.35 trading range for a while until we get anything of a substance, either positive or negative. The lift itself is not a stock mover. Even an FDA approval of a modified AXAL trial will not move the needle as it implies the cash burn will be higher for two years or so -- not sustainable in any way. They need to sell or partner AXAL. Technically, ADXS can hardly support one single clinical trial, but they're running 4 now on my count. It's not sustainable at all. They'll be either forced to terminate 2 or 3 trials, or sell these at a big discount before this collapses pretty soon.
Amen !